-
8581por Ivanov, Alexander V., Bartosch, Birke, Smirnova, Olga A., Isaguliants, Maria G., Kochetkov, Sergey N.“…Hepatitis C virus (HCV) is the etiological agent accounting for chronic liver disease in approximately 2–3% of the population worldwide. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8582por Mangioni, Davide, Soria, Alessandro, Brighina, Laura, Bandera, Alessandra, Ferrarese, Carlo, Gori, Andrea“…BACKGROUND: Despite recent development of direct acting antivirals for treatment of hepatitis C, the current standard of care may still include pegylated-interferon, which is associated with frequent and, at times, serious adverse events. …”
Publicado 2014
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8583por Cortés-Telles, Arturo“…Pulmonary toxicity related to the use of pegylated interferon alpha-2a during treatment of hepatitis C infections is rare; nonetheless, some cases with fatal outcomes have been reported. …”
Publicado 2016
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8584por Lafferty, Lise, Treloar, Carla, Butler, Tony, Guthrie, Jill, Chambers, Georgina M.“…This study seeks to identify and understand social capital dimensions among incarcerated men living with hepatitis C. METHODS: In-depth interviews were conducted across three correctional centres in New South Wales with 30 male inmates living with hepatitis C. …”
Publicado 2016
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8585por Hunyady, Bela, Jaroszewicz, Jerzy, Lipták, Ľubomír, Skladaný, Ľubomír, Sperl, Jan, Šváč, Juraj“…All these topics are or have been of high interest during the last several years, and many of them are still not completely resolved with the emergence and availability of the novel interferon-free therapies for hepatitis C and with other advances in the pathophysiology and treatment of liver diseases.…”
Publicado 2016
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8586“…Other infections, including human immunodeficiency virus and hepatitis C, are uncommon but potentially life threatening. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8587“…BIT225, developed by Biotron Limited, is the first acylguanidine in clinical trials against HIV type 1 and hepatitis C virus. In this article we focus on the mechanisms of inhibition of viral proteins by acylguanidines.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8588por Cox, Andrea L., El-Sayed, Manal H., Kao, Jia-Horng, Lazarus, Jeffrey V., Lemoine, Maud, Lok, Anna S., Zoulim, Fabien“…The global burden of viral hepatitis is substantial; in terms of mortality, hepatitis B virus and hepatitis C virus infections are on a par with HIV, malaria and tuberculosis, among the top four global infectious diseases. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8589por Nagao, Yumiko“…Alternatively, the dentist might discover patients with untreated hepatitis C and hepatitis B during routine dental examination. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8590“…AF can also develop in other clinical situations such as organ transplantation, cancer chemotherapy, and under treatment for chronic hepatitis B or treatment for chronic hepatitis C in patients with co-infected hepatitis B/hepatitis C. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8591por Bilar, Juliana Miguel, Carvalho-Filho, Roberto José, Mota, Carolina Frade Magalhães Girardin Pimentel, da Silva Fucuta, Patricia, Ferraz, Maria Lucia Cardoso Gomes“…Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30–50%. …”
Publicado 2014
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8592“…Despite the advancement in antiviral therapy, Hepatitis C remains a global health challenge and one of the leading causes of hepatitis related deaths worldwide. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8593por Shreya, Sunidhi, Chawla, Rohit, Anuradha, S., Singh, Mongjam Meghachandra, Manchanda, Vikas, Saxena, Sonal“…RESULTS: The prevalence of syphilis, hepatitis B, and hepatitis C was observed in 3.5%, 2%, and 10% of patients, respectively. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8594por Rosmarin-DeStefano, Corey L, Slim, Jihad, Tempalski, Barbara, Leyden, Kevin, Levaggi, Emily, Duprey, Sheena, Torres, Juan, Chavez, Evelyn“…BACKGROUND: North Jersey Community Research Initiative (NJCRI) in Newark, New Jersey has piloted the addition of an innovative community based contracted pharmacy to their mobile hepatitis C clinic to provide seamless care and coordination to the patient. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8595por Suzuki, Hitoshi, Matsumoto, Norihiko, Suzuki, Tomoyuki, Chang, Myint OO, Takaku, Hiroshi“…BACKGROUND: Hepatitis C virus (HCV) is one of the main causes of liver-related morbidity and mortality. …”
Publicado 2009
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
8596“…The common presenting symptom was bleeding following male circumcision. Hepatitis C infection and arthropathy represented the main complications. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
8597por Khairy, Marwa, Abdel-Rahman, Mahassen, El-Raziky, Maissa, El-Akel, Wafaa, Zayed, Naglaa, Khatab, Hany, Esmat, Gamal“…OBJECTIVES: Our aim was to assess noninvasive predictors of fibrosis in patients with chronic hepatitis C using the routine laboratory pre-treatment workup. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8598por Lange, Christian M., Miki, Daiki, Ochi, Hidenori, Nischalke, Hans-Dieter, Bojunga, Jörg, Bibert, Stéphanie, Morikawa, Kenichi, Gouttenoire, Jérôme, Cerny, Andreas, Dufour, Jean-François, Gorgievski-Hrisoho, Meri, Heim, Markus H., Malinverni, Raffaele, Müllhaupt, Beat, Negro, Francesco, Semela, David, Kutalik, Zoltan, Müller, Tobias, Spengler, Ulrich, Berg, Thomas, Chayama, Kazuaki, Moradpour, Darius, Bochud, Pierre-Yves“…We therefore aimed to determine the relationship between genetic determinants of vitamin D serum levels and the risk of developing hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8599por Spaniel, Carolyn, Honda, Masao, Selitsky, Sara R., Yamane, Daisuke, Shimakami, Tetsuro, Kaneko, Shuichi, Lanford, Robert E., Lemon, Stanley M.“…Mechanisms of hepatic carcinogenesis in chronic hepatitis B and hepatitis C are incompletely defined but often assumed to be similar and related to immune-mediated inflammation. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8600por Jiang, Weimin, Hidaka, Hisashi, Nakazawa, Takahide, Kitagawa, Hiroyuki, Koizumi, Wasaburo“…BACKGROUND: Pegylated interferon combined with ribavirin treatment is an effective therapy for chronic hepatitis C viral infection. However, pegylated interferon combined with ribavirin is associated with various adverse reactions. …”
Publicado 2014
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto